Table 3 Meta-analysis outcomes of adverse reactions for liver cancer treatment with camrelizumab combined with apatinib
adverse event | Any grade | Grade ≥ 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
study | Heterogeneity | ES (95%CI) | P | P(Egger) | study | Heterogeneity | ES (95%CI) | P | P(Egger) | |||
P | I2(%) | P | I2(%) | |||||||||
Total | 6 | 0.000 | 92.8 | 0.90(0.85,0.95) | 0.000 | 0.420 | 6 | 0.000 | 97.7 | 0.49(0.27,0.71) | 0.000 | 0.250 |
Thrombocytopenia | 3 | 0.031 | 71.3 | 0.51(0.41,0.62) | 0.000 | 0.020 | 3 | 0.000 | 88.7 | 0.09(0.01,0.17) | 0.034 | 0.277 |
Hypertension | 7 | 0.000 | 95.6 | 0.45(0.27,0.62) | 0.000 | 0.829 | 5 | 0.000 | 98.5 | 0.19(0.04,0.34) | 0.011 | 0.063 |
Hand-foot skin reaction | 5 | 0.000 | 84.1 | 0.45(0.33,0.57) | 0.000 | 0.201 | 4 | 0.218 | 32.4 | 0.06(0.03,0.09) | 0.000 | 0.693 |
Leukopenia | 3 | 0.001 | 85.8 | 0.40(0.26,0.55) | 0.000 | 0.422 | NR | |||||
Abdominal pain | 4 | 0.017 | 70.7 | 0.34(0.24,0.44) | 0.000 | 0.421 | 3 | 0.466 | 0.00 | 0.02(0.00,0.03) | 0.017 | 0.323 |
Proteinuria | 6 | 0.000 | 97.1 | 0.37(0.17,0.56) | 0.000 | 0.797 | 4 | 0.114 | 49.7 | 0.05(0.02,0.07) | 0.000 | 0.906 |
Diarrhea | 3 | 0.711 | 0.0 | 0.31(0.26,0.36) | 0.000 | 0.203 | 2 | 0.661 | 0.0 | 0.02(0.00,0.04) | 0.015 | - |
Hepatotoxicity | 2 | 0.000 | 97.8 | 0.24(0.18,0.66) | 0.260 | - | 2 | 0.589 | 0.0 | 0.03(0.01,0.06) | 0.003 | - |
Fever | 2 | 0.003 | 88.7 | 0.20(0.15,0.54) | 0.261 | - | NR | |||||
Hypothyroidism | 6 | 0.000 | 85.2 | 0.20(0.12,0.27) | 0.000 | 0.616 | NR | |||||
Rash | 5 | 0.000 | 87.8 | 0.18(0.09,0.27) | 0.000 | 0.653 | 4 | 0.195 | 36.2 | 0.01(0.00,0.03) | 0.057 | 0.088 |
Fatigue | 4 | 0.163 | 41.4 | 0.17(0.11,0.22) | 0.000 | 0.843 | NR | |||||
RCCEP | 4 | 0.003 | 78.3 | 0.19(0.10,0.27) | 0.000 | 0.295 | NR | |||||
Nausea and vomiting | 3 | 0.885 | 0.0 | 0.11(0.08,0.14) | 0.000 | 0.453 | NR | |||||